Research programme: allergic rhinitis vaccine - AFFiRiS
Latest Information Update: 18 Jan 2016
At a glance
- Originator AFFiRiS
- Class Allergy immunotherapies; Antiallergics; Peptide vaccines
- Mechanism of Action Immunoglobulin E modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Allergic rhinitis
Most Recent Events
- 18 Jan 2016 Preclinical trials in Allergic rhinitis in Austria (unspecified route)